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Microparticles (MPs) are membrane vesicles of 0.1–1 
μm in diameter shed from vascular endothelium and 
blood cells (e.g.: lymphocytes T and B, macrophages) 
or platelets in response to cell activation, various forms 
of stress (e.g. hypoxia, mechanical trauma or infl am-
mation). MPs can be also released during malignant 
transformation or apoptosis [1]. The mechanism of 
MPs formation can be studied by stimulating cultured 
cells in vitro with numerous cytokines and apoptotic 
stimuli [2]. The role of MPs in various diseases can 
be explored by their isolation from peripheral blood 
[3]. So far the endothelial MPs and platelet (PMPs) 
microparticles have been studied extensively in cancer, 
atherosclerosis, sepsis, diabetes and cardiovascular dis-
eases [1, 3].
Additionally to MPs, exosomes (Ex) and apop-
totic bodies are sometimes considered members of 
„microparticles family”. However, MPs have different 
size, biological properties release mechanism [4, 5]. 
Apoptotic bodies are cell fragments formed in the ter-
minal phase of apoptosis during cell fragmentation, 
they are larger than MPs and, like exosomes, exhibit 
lower clotting capacity comparing to MPs. While Ex 
are produced in the endocytic-lysosomal system and 
released from cell by the fusion of multivesicular bod-
ies (MVB) with plasma membrane, MPs are formed by 
cell membrane shedding [6, 7] (Figure 1). The essential 
feature of this process is the loss of the cell membrane 
asymmetric phospholipid distribution in response to 
the increased intracellular calcium levels. This in turn 
regulates membrane fl ippase, fl oppase and scramblase 
activity, leading to phosphatidylserine (PS) and phos-
phatidylethanolamine (PE) exposure on the outer mem-
brane leafl et, and the activation of contractile proteins 
(Figure 2). PS is a negatively charged phospholipid 
and, in the presence of calcium ions, it assembles the 
prothrombinase complex and activates coagulation in 
vivo [3].
PMPs are the most abundant circulating MP sub-
type [1]. They are released from platelets after their 
activation by thrombin, ADP plus collagen, calcium 
ionophore A23187 and high shear stress. Endothe-
lial cells, monocytes and vascular smooth cells can 
release MPs after activation by bacterial lipopolysac-
charide, infl ammatory cytokines (e.g. interleukin-1α, 
IL-1α), complement complex C5b-9 or reactive oxy-
gen species, hyperhomocysteinemia, hyperglycemia, 
hypoxia and tumor necrosis factor α [8, 9, 10]. MPs 
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contain enzymes and genetic material which enables 
them to interact and infl uence target cell (Figure 3) 
[7]. Endothelial MPs transfer cell adhesion protein VE-
cadherin, T-cadherin, E-selectin and sialomucin (CD34). 
Endothelial MPs are also the carrier of many active 
enzymes, including matrix metalloproteinases and their 
inhibitors acid sphingomyelinase, nitric oxide synthas-
es (eNOS), NADPH oxidase. These microparticles also 
regulate intercellular lipid transfer (PS, PA, sphingomy-
elin, arachidonic acid). Additionally, MPs contain DNA, 
mRNA, microRNA- and, possibly, other non-coding 
nucleic acid chains, indicating that MPs may play a role 
in the cell-to-cell transfer of genetic contents [11].
MPs play role in infl ammation, coagulation and 
vascular function and are considered to be markers 
of ongoing pathophysiological processes. All of these 
processes contribute to cardiovascular risk factors (e.g.: 
diabetes and hypertension) or disorders (e.g.: athero-
sclerosis, coronary artery disease, stroke, cardiomyopa-
thy or thromboembolism) [2, 3]. 
Figure 1. The comparison of exosomes (Ex) and microparticles (MPs). AF – actin fi laments, FU – fusion of cell and vesicle membrane, MVB – multive-
sicular body, Sh – membrane shedding
Figure 2. The regulation and physiology of cell membrane budding and microparticle formation. This model describes the stages of cell activation leading 
to membrane phospholipid asymmetry. The fi rst step is cell stimulation via ligand-to-receptor binding (1a) or calcium channel activation (1b). A recep-
tor transmits a signal towards the cell (2a) and/or calcium infl ux occurs (2b). Increased calcium activates calpain to brake F-actin and release spectrin 
from submembrane compartments (3a, 3b) or evokes RhoA phosphorylation (4). Membrane lipid asymmetry is regulated by the cooperative activities 
of three transporters: (fl ippase) the ATP-dependent aminophospholipid-specifi c translocase, which rapidly transports PS and PE from the cell's outer-to-
inner leafl et; the ATP-dependent nonspecifi c lipid fl oppase, which slowly transports lipids from the cell's inner-to-outer leafl et; and the Ca2+-dependent 
nonspecifi c lipid scramblase, which allows lipids to move randomly between both leafl ets (5). Finally, a microvessicle is formed and myosin II contraction 
controls its release (6)
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Atherosclerosis is an infl ammatory process caused 
largely by transendothelial migration and accumula-
tion of macrophages and neutrophils in the arterial wall 
[12]. The endothelial MPs stimulate endothelial cells to 
secrete cytokines responsible for activation and chemot-
action of leukocytes [13]. Platelet MPs, by delivering 
arachidonic acid to endothelial cells, increase adhesion 
of monocytes to human umbilical vein endothelial cells 
(HUVEC), following upregulation of cellular adhesion 
molecules (ICAM-1) on endothelium and CD11a/CD18 
and CD11b/CD18 on monocytes [14]. Leukocyte to leu-
kocyte adhesion is also mediated by platelet MPs thor-
ough the up-regulation of CD11b on cell surface. After 
the arterial wall is infi ltrated with leukocytes, they start 
to secrete cytokines and growth factors that activate 
the proliferation of vascular smooth muscle cells, and 
initiates formation of atherosclerotic plaque [15].
Coagulation (thrombogenesis) is an important part 
of hemostasis. Cardiovascular patients are at high risk 
of thrombosis and they are predisposed to develop 
serious adverse cardiovascular events such as myocar-
dial infarction, stroke, and acute lower limb ischemia. 
MPs have a large impact on coagulation mainly from 
the exposure of negatively charged PS on the outer 
membrane leafl et [5]. In the presence of calcium ions 
PS forms the prothrombinase complex assembly and 
increases thrombogenesis. Moreover, activated factor V 
(a clotting activator) can be found at the MPs surface. 
In the presence of calcium and phospholipids, an acti-
vated factor V merges with an activated factor X to pro-
duce thrombin (protrombinase activity). In turn, to cata-
lyze factor X conversion to its active form, the complex 
of tissue factor (TF) with factor VIIa is necessary. That 
again leads to MPs because TF is present in the surface 
of platelet-derived microvesicles [16]. In patients with 
myocardial infarction the higher coagulation plasma 
potential due to MPs can be assumed (Figure 4).
Boulanger et al. (2001) showed the MPs impact on 
the vascular function [17]. Authors exposed rat aor-
tic rings (with endothelium) for 24 hours to circulat-
ing MPs isolated from 7 non-ischemic patients and 19 
patients with acute myocardial infarction. They found 
Figure 3. The scheme of typical EMP content. CAM – cell adhesion molecules, eNOS – endothelial nitric oxide synthase, EPC – endothelial protein C, 
MMP – matrix metalloproteinase, TF – tissue factor, TM – thrombomodulin, uPA/tPA – urokinase/tissue plasminogen activator, uPAR – urokinase plas-
minogen activator receptor. Based on Stępień and Targosz-Korecka 2013 [7], with agreement and modifi ed
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that endothelium-dependent relaxations to acetylcho-
line were reduced in samples exposed to MPs from 
patients with myocardial infarction but not from non-
ischemic patient [17]. 
Many in vivo studies regarding MPs in cardiovascular 
diseases, concerning their overall amount and composi-
tion, have been published in recent years, e.g.: endothe-
lial MP levels were elevated comparing to control in deep 
vein thrombosis or pulmonary embolism [18], in acute 
coronary syndrome [19], in acute ischemic stroke [20], 
in diabetes [21, 22] or in the severe hypertension with 
systolic pressure correlation [23]. Very interesting study 
was carried out in 2005 by Koga et al. who proved that 
elevated endothelial MP levels were predictive for the 
presence of coronary artery lesions in diabetic patients 
referred for coronary angiography these microparticles 
were the strongest risk factor for CAD irrespective of 
other risk factors such as length of diabetic disease, lip-
id concentration, and hypertension. The elevated EMP 
were particularly useful in identifying patients with 
angiographically confi rmed coronary artery disease and 
without typical angina symptoms [24].
In summary, MPs are diverse biological objects with 
various structure and function. Their impact on coagu-
lation, infl ammation and vascular function is impor-
tant for endothelial function [25]. Precise knowledge 
of their release and activity in vivo may help to identify 
patients with increased cardiovascular risk in the future 
and perhaps apply appropriate therapies before acute 
complications occur.
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